Ledger.Open graph →
SEC Form D · filed June 20, 2017

Anelixis Therapeutics, Inc

Offering
$8.0M
Sold
$4.3M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (16)

Paul Sallaberry · San Francisco, CADirectorKent Bransford · CAMBRIDGE, MADirectorMaeve Mcnally · CAMBRIDGE, MAExecTheodore Reich · CAMBRIDGE, MADirectorSteven Perrin · CAMBRIDGE, MAExec · DirectorAugie Nieto · CAMBRIDGE, MADirectorEric Craven · CAMBRIDGE, MADirectorJames Heywood · Newton, MADirectorKent Bransford · CAMBRIDGE, MADirectorMaeve Mcnally · CAMBRIDGE, MAExecTheodore Reich · CAMBRIDGE, MADirectorSteven Perrin · CAMBRIDGE, MAExec · DirectorPaul Sallaberry · SANTA CLARA, CADirectorAugie Nieto · CAMBRIDGE, MADirectorEric Craven · CAMBRIDGE, MADirectorJames Heywood · Cambridge, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗